Drug intelligence / Profile preview

HB-502

Development stage: Unknown
Lead developer: HOOKIPA Pharma
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

HB-502 is an arenavirus-based viral vector therapy developed by HOOKIPA Pharma for the treatment of Human Immunodeficiency Virus (HIV). It utilizes a proprietary arenavirus platform (specifically a Pichinde virus vector) engineered to express HIV-1 antigens, including Gag, Pol, and Nef. HB-502 is designed to be used in a heterologous prime-boost regimen alongside HB-501 (a Lymphocytic Choriomeningitis Virus vector) to induce high-magnitude, polyfunctional CD8+ T cell responses. This approach aims to achieve immune-mediated control of viral replication and potentially provide a functional cure for HIV in patients currently suppressed on antiretroviral therapy (ART).

Other names: HB-502HB502HB 502

Targets

Human immunodeficiency virus type 1 reverse transcriptaseNef (HIV-1 Nef)Gag (HIV-1 Gag polyprotein)

Beyond the preview

Go deeper on HB-502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HB-502.

Explore the full profile